111 related articles for article (PubMed ID: 30060952)
1. Stabilization of HDAC1 via TCL1-pAKT-CHFR axis is a key element for NANOG-mediated multi-resistance and stem-like phenotype in immune-edited tumor cells.
Woo SR; Lee HJ; Oh SJ; Kim S; Park SH; Lee J; Song KH; Kim TW
Biochem Biophys Res Commun; 2018 Sep; 503(3):1812-1818. PubMed ID: 30060952
[TBL] [Abstract][Full Text] [Related]
2. HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells.
Song KH; Choi CH; Lee HJ; Oh SJ; Woo SR; Hong SO; Noh KH; Cho H; Chung EJ; Kim JH; Chung JY; Hewitt SM; Baek S; Lee KM; Yee C; Son M; Mao CP; Wu TC; Kim TW
Cancer Res; 2017 Sep; 77(18):5039-5053. PubMed ID: 28716899
[TBL] [Abstract][Full Text] [Related]
3. HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors.
Song KH; Oh SJ; Kim S; Cho H; Lee HJ; Song JS; Chung JY; Cho E; Lee J; Jeon S; Yee C; Lee KM; Hewitt SM; Kim JH; Woo SR; Kim TW
Nat Commun; 2020 Jan; 11(1):562. PubMed ID: 31992715
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer.
Wang Y; Wang Y; Wang N; You L; Long F; Shao C; Wang Y; Wu J
Oncol Rep; 2019 Oct; 42(4):1467-1474. PubMed ID: 31322269
[TBL] [Abstract][Full Text] [Related]
5. Suppression of the SAP18/HDAC1 complex by targeting TRIM56 and Nanog is essential for oncogenic viral FLICE-inhibitory protein-induced acetylation of p65/RelA, NF-κB activation, and promotion of cell invasion and angiogenesis.
Ding X; Xu J; Wang C; Feng Q; Wang Q; Yang Y; Lu H; Wang F; Zhu K; Li W; Yan Q; Gao SJ; Lu C
Cell Death Differ; 2019 Oct; 26(10):1970-1986. PubMed ID: 30670829
[TBL] [Abstract][Full Text] [Related]
6. Chfr is linked to tumour metastasis through the downregulation of HDAC1.
Oh YM; Kwon YE; Kim JM; Bae SJ; Lee BK; Yoo SJ; Chung CH; Deshaies RJ; Seol JH
Nat Cell Biol; 2009 Mar; 11(3):295-302. PubMed ID: 19182791
[TBL] [Abstract][Full Text] [Related]
7. LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells.
Kim S; Cho H; Hong SO; Oh SJ; Lee HJ; Cho E; Woo SR; Song JS; Chung JY; Son SW; Yoon SM; Jeon YM; Jeon S; Yee C; Lee KM; Hewitt SM; Kim JH; Song KH; Kim TW
Autophagy; 2021 Aug; 17(8):1978-1997. PubMed ID: 32762616
[TBL] [Abstract][Full Text] [Related]
8. CHFR regulates chemoresistance in triple-negative breast cancer through destabilizing ZEB1.
Luo H; Zhou Z; Huang S; Ma M; Zhao M; Tang L; Quan Y; Zeng Y; Su L; Kim J; Zhang P
Cell Death Dis; 2021 Aug; 12(9):820. PubMed ID: 34462429
[TBL] [Abstract][Full Text] [Related]
9. TOPK and PTEN participate in CHFR mediated mitotic checkpoint.
Shinde SR; Gangula NR; Kavela S; Pandey V; Maddika S
Cell Signal; 2013 Dec; 25(12):2511-7. PubMed ID: 24012691
[TBL] [Abstract][Full Text] [Related]
10. The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.
Zhang X; Feng Y; Wang XY; Zhang YN; Yuan CN; Zhang SF; Shen YM; Fu YF; Zhou CY; Li X; Cheng XD; Lu WG; Xie X
Cell Death Dis; 2018 Jan; 9(2):93. PubMed ID: 29367628
[TBL] [Abstract][Full Text] [Related]
11. The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition.
Kang D; Chen J; Wong J; Fang G
J Cell Biol; 2002 Jan; 156(2):249-59. PubMed ID: 11807090
[TBL] [Abstract][Full Text] [Related]
12. CHFR promotes metastasis of human gastric carcinoma by activating AKT and ERK via NRF2- ROS axis.
He F; Ye B; Wu X; Pan J; Wang J; Wang X
BMC Gastroenterol; 2023 Apr; 23(1):114. PubMed ID: 37024798
[TBL] [Abstract][Full Text] [Related]
13. CHFR-mediated degradation of RNF126 confers sensitivity to PARP inhibitors in triple-negative breast cancer cells.
Wu W; Zhao J; Xiao J; Wu W; Xie L; Xie X; Yang C; Yin D; Hu K
Biochem Biophys Res Commun; 2021 Oct; 573():62-68. PubMed ID: 34388456
[TBL] [Abstract][Full Text] [Related]
14. Nanog signaling in cancer promotes stem-like phenotype and immune evasion.
Noh KH; Kim BW; Song KH; Cho H; Lee YH; Kim JH; Chung JY; Kim JH; Hewitt SM; Seong SY; Mao CP; Wu TC; Kim TW
J Clin Invest; 2012 Nov; 122(11):4077-93. PubMed ID: 23093782
[TBL] [Abstract][Full Text] [Related]
15. Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle.
Oh SJ; Lee HJ; Song KH; Kim S; Cho E; Lee J; Bosenberg MW; Kim TW
J Clin Invest; 2022 Mar; 132(6):. PubMed ID: 35104240
[TBL] [Abstract][Full Text] [Related]
16. CHFR negatively regulates SIRT1 activity upon oxidative stress.
Kim M; Kwon YE; Song JO; Bae SJ; Seol JH
Sci Rep; 2016 Nov; 6():37578. PubMed ID: 27883020
[TBL] [Abstract][Full Text] [Related]
17. The anti-proliferative effects of the CHFR depend on the forkhead associated domain, but not E3 ligase activity mediated by ring finger domain.
Fukuda T; Kondo Y; Nakagama H
PLoS One; 2008 Mar; 3(3):e1776. PubMed ID: 18335050
[TBL] [Abstract][Full Text] [Related]
18. CHFR is negatively regulated by SUMOylation-mediated ubiquitylation.
Bae SJ; Kwon YE; Kim M; Seol JH
Biochem Biophys Res Commun; 2013 Apr; 433(2):194-9. PubMed ID: 23454125
[TBL] [Abstract][Full Text] [Related]
19. NANOG signaling promotes metastatic capability of immunoedited tumor cells.
Lee HJ; Noh KH; Lee YH; Song KH; Oh SJ; Kim SY; Kim TW
Clin Exp Metastasis; 2015 Jun; 32(5):429-39. PubMed ID: 25899063
[TBL] [Abstract][Full Text] [Related]
20. CHFR‑mediated epithelial‑to‑mesenchymal transition promotes metastasis in human breast cancer cells.
Jiang G; Fang H; Shang X; Chen X; Cao F
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33880594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
